专题：Platelet Disorders and Treatments

This cluster of papers focuses on platelet disorders, thrombosis mechanisms, and related conditions such as immune thrombocytopenic purpura and von Willebrand disease. It covers topics including platelet function, hemostasis, inflammation, megakaryocyte development, and the molecular mechanisms underlying thrombus formation.
最新文献
Structure and multiple functions of von Willebrand factor

article Full Text OpenAlex

Von Willebrand disease: classification and epidemiology

article Full Text OpenAlex

Historical, current and future treatments for von Willebrand disease

article Full Text OpenAlex

Clinical and laboratory diagnosis of von Willebrand disease

article Full Text OpenAlex

Gynecologic and obstetric management of girls and women with von Willebrand disease

article Full Text OpenAlex

Molecular genetic testing in von Willebrand disease: past, present, and beyond

article Full Text OpenAlex

The landmark contribution by Erik von Willebrand

article Full Text OpenAlex

Balancing Bleeding and Clot: Type 2 Heparin-Induced Thrombocytopenia With Extensive Thromboses in a Patient With Subdural Hematoma

article Full Text OpenAlex

Immune thrombocytopenia triggered by dostarlimab in a patient with endometrial carcinoma: first reported case

article Full Text OpenAlex

A case of superficial pemphigus induced by sodium valproate

article Full Text OpenAlex

近5年高被引文献
2023 ACR/EULAR antiphospholipid syndrome classification criteria

article Full Text OpenAlex 349 FWCI142.39993238

Long-Term Outcomes in IgA Nephropathy

article Full Text OpenAlex 296 FWCI95.81260681

The role of platelets in immune-mediated inflammatory diseases

review Full Text OpenAlex 264 FWCI104.55808813

Tetraspanins distinguish separate extracellular vesicle subpopulations in human serum and plasma – Contributions of platelet extracellular vesicles in plasma samples

article Full Text OpenAlex 219 FWCI26.21373065

Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management

review Full Text OpenAlex 216 FWCI88.6408801

Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

article Full Text OpenAlex 208 FWCI67.88079601

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

article Full Text OpenAlex 206 FWCI66.58164202

Beyond Hemostasis: Platelet Innate Immune Interactions and Thromboinflammation

review Full Text OpenAlex 205 FWCI45.58347381

The therapeutic age of the neonatal Fc receptor

review Full Text OpenAlex 202 FWCI64.28343278

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

article Full Text OpenAlex 196 FWCI40.48668868